Transforming treatments for schizophrenia: Investigating changes in Electroencephalogram (EEG) theta spectral power at the right temperoparietal junction (rTPJ) following combined virtual reality and theta tACS.

Monash University0 个研究点目标入组 46 人开始时间: 2021年12月1日最近更新: 2021年12月13日

适应症

试验速览

暂无简介。

•Participants with a diagnosis of schizophrenia or schizoaffective disorder:
•-Adults between 18 and 55 years of age.
•-Diagnosis of schizophrenia or schizoaffective disorder as confirmed by the MINI 7.0.2.
•-Ability to provide informed consent and show understanding of participation by relaying key information to researcher.
•Healthy Volunteers:
•-Adults aged 18-55 years
•-No history of mental illness confirmed with MINI
•-No unstable medical conditions
•-No contraindications to receiving tACS (mentioned in exclusion criteria)

•-Commencement or significant dosage alteration of other psychotropic medications (i.e., anti-depressants, anti-psychotics) during the four weeks prior to an experimental session.
•-Currently taking any medication shown to interfere with the effects of tACS; namely benzodiazepines
•-A current substance use or alcohol use disorder
•-Any history of significant head injury or traumatic brain injury, as defined by a loss of consciousness greater than 30 minutes or requiring a hospital admission.
•-Unstable medical or neurological illness.
•-Pregnancy or breastfeeding.
•-An uncorrected hearing or visual impairment (including difficulty with colour perception).
•-Significant difficulties with understanding or communicating in English.

发起方